Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

by · The Cerbat Gem

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 552,800 shares, an increase of 15.2% from the September 15th total of 479,700 shares. Based on an average daily volume of 144,200 shares, the short-interest ratio is currently 3.8 days. Approximately 3.4% of the company’s stock are short sold.

Immix Biopharma Trading Down 1.4 %

NASDAQ IMMX traded down $0.02 on Wednesday, hitting $1.44. 98,889 shares of the stock traded hands, compared to its average volume of 187,247. The company has a market capitalization of $38.04 million, a P/E ratio of -1.51 and a beta of 0.12. The stock has a 50-day moving average of $1.83 and a 200 day moving average of $2.10. Immix Biopharma has a twelve month low of $1.26 and a twelve month high of $7.75.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. As a group, equities research analysts expect that Immix Biopharma will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned 0.10% of Immix Biopharma at the end of the most recent reporting period. Institutional investors and hedge funds own 11.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Thursday, October 3rd.

Read Our Latest Report on Immix Biopharma

About Immix Biopharma

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

Featured Stories